The University Hospital St. Marina – Varna is a university hospital in Varna, Bulgaria. The hospital has capacity of 1200 beds.

There are 1,200 beds in Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD.

During the past decade, Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 10 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 8 clinical trials were completed. i.e. 133.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD" #1 sponsor was "Celgene" with 6 trials, followed by "Amgen" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "AOP Orphan Pharmaceuticals AG" with 1 trials sponsored and "Astex Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "ICON plc" with 1 trials as a collaborator, "Medidata Solutions" with 1 trials as a collaborator, "PPD" with 1 trials as a collaborator and "PharmaEssentia Corporation (for the U.S.)" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD" are "Small Cell Lung Cancer" (2 trials), "Ulcerative Colitis" (2 trials), "B-Cell Chronic Lymphocytic Leukemia" (1 trials), "Beta-Thalassemia" (1 trials) and "Beta-thalassemia" (1 trials). Many other conditions were trialed in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD" in a lesser frequency.

Most popular intervention types in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD" are "Drug" (21 trials), "Other" (3 trials), "Biological" (1 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Luspatercept" (2 trials), "Melphalan" (2 trials), "Ozanimod" (2 trials) and "Accordion Pill™ Carbidopa/Levodopa" (1 trials). Other intervention names were less common.

The vast majority of trials in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD" are 21 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Multiprofile Hospital for Active Treatment "Sveta Marina'' EAD, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".